Ligand Pharmaceuticals Inc. Announces Highlights From Presentation At The 26th Annual Roth Capital Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented today at the Roth Capital Conference in Dana Point, California, where it reviewed its business and financial highlights, its unique R&D model and selected un-partnered programs, and provided partnering case studies.

Highlights of today’s presentation by Ligand management included the following:

•Of Ligand’s over 90 “shots-on-goal,” 14 new programs could potentially launch by the end of 2017. Five new programs or indications in Ligand’s portfolio could potentially launch in 2014, up from four presented previously and four new programs could launch in 2017, up from one presented previously.

Help employers find you! Check out all the jobs and post your resume.